Affiliation:
1. From the Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson, MS; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo; Obstetrics and Gynecology, Division of Gynecologic Oncology, Albany Medical Center Hospital, Albany; Department of Obstetrics and Gynecology, University of Rochester School of Medicine, Rochester, NY; Wake Forest University School of Medicine, Winston-Salem, NC; Department of Obstetrics and...
Abstract
Purpose Doxorubicin and cisplatin have activity in endometrial carcinoma and at initiation of this study ranked as the most active agents. This trial of stage III, IV, or recurrent disease evaluated whether combining these agents increases response rate (RR) and prolongs progression-free survival (PFS) and overall survival (OS) over doxorubicin alone. Patients and Methods Of 299 patients registered, 281 (94%) were eligible. Regimens were doxorubicin 60 mg/m2 intravenously or doxorubicin 60 mg/m2 plus cisplatin 50 mg/m2 every 3 weeks until disease progression, unacceptable toxicity, or a total of 500 mg/m2 doxorubicin. Results There were 12 (8%) complete (CR) and 26 (17%) partial responses (PR) among 150 patients receiving doxorubicin versus 25 (19%) CRs and 30 (23%) PRs among patients receiving the combination. The overall response rate was higher among patients receiving the combination (42%) compared with patients receiving doxorubicin (25%; P = .004). Median PFS was 5.7 and 3.8 months, respectively, for the combination and single agent. The PFS hazard ratio was 0.736 (95% CI, 0.577 to 0.939; P = .014). Median OS was 9.0 and 9.2 months, respectively, for the combination and single agent. Overall death rates were similar in the two groups (hazard ratio, 0.928; 95% CI, 0.727 to 1.185). Nausea, vomiting, and hematologic toxicities were common. The combination produced more grade 3 to 4 leukopenia (62% v 40%), thrombocytopenia (14% v 2%), anemia (22% v 4%), and nausea/vomiting (13% v 3%). Conclusion Adding cisplatin to doxorubicin in advanced endometrial carcinoma improves RR and PFS with a negligible impact on OS and produces increased toxicity. These results have served as a building block for subsequent phase III trials in patients with disseminated and high-risk limited endometrial carcinoma.
Publisher
American Society of Clinical Oncology (ASCO)
Reference29 articles.
1. Perspectives on research in gynecologic oncology.Treatment protocols
2. Thigpen JT, Buchsbaum H, Mangan C, et al: Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Cancer Treat Rep 63:21,1979-27,
3. Phase II trial of clsplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A gynecologic oncology group study
4. Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study
5. Randall ME, Brunetto G, Muss H, et al: Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group. Proc Am Soc Clin Oncol 22:2,2003, (abstr 3)
Cited by
331 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献